1 Subjects: “...Biological Products / therapeutic use...”

2 Subjects: “...Biological Products / therapeutic use...”

3 “... associated side effects including drowsiness, dizziness and dry mouth; according to the product monograph...”

4 “...In 2017, CADTH produced a Rapid Response report summarizing evidence on the clinical effectiveness...”

5 “... associated side effects including drowsiness, dizziness and dry mouth; according to the product monograph...”

6 “...In 2017, CADTH produced a Rapid Response report summarizing evidence on the clinical effectiveness...”

7 “... the time needed for normal tissue healing. It can impact the individual's quality of life and productivity...”

8 “..., administration of blood product) in pre-hospital settings, and to examine clinical guidelines regarding the use...”

9 “... the time needed for normal tissue healing. It can impact the individual's quality of life and productivity...”

10 “...), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary...”

11 “..., administration of blood product) in pre-hospital settings, and to examine clinical guidelines regarding the use...”

12 “... or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD....”

13 “...), and received a recommendation of "do not list". CADTH has previously produced a Rapid Response Summary...”

14 “... or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD....”

15

16

17 “.... For instance, the combination product piperacillin-tazobactam is often referred to as monotherapy unless...”

18

19 “.... For instance, the combination product piperacillin-tazobactam is often referred to as monotherapy unless...”

20